Literature DB >> 1451728

Pharmacokinetics of pirmenol in young and elderly subjects.

D G Ferry1, A J Campbell, R Bland, M Beasley, L Gazeley, I R Edwards.   

Abstract

The steady state pharmacokinetics of pirmenol was compared in twelve healthy young (aged 18 to 45 y) and 11 elderly subjects (over 65 y) subjects given pirmenol HCl 100 mg every 12 h for a total of 14 doses. In addition, the single-dose pharmacokinetics of pirmenol was determined following a 100 mg oral dose in the young subject group for comparison with the results of repeated administration. In the young subjects, the mean single-dose and steady-state CLR of pirmenol were similar; however, Ae was 29% higher and CL/f was 22% lower at steady state than after the single dose. Steady-state (fourteenth dose) Cmin, Cmax, tmax, lambda z, Ae, CL/f, CLR and V values were similar in the young and elderly subjects. Based on pharmacokinetic considerations, the dosage of pirmenol is unlikely to differ in young and elderly subjects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1451728     DOI: 10.1007/bf02220624

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

Review 1.  Aging and drug disposition: an update.

Authors:  D L Schmucker
Journal:  Pharmacol Rev       Date:  1985-06       Impact factor: 25.468

2.  Disposition of intravenous pirmenol.

Authors:  S W Sanders; J M Nappi; R L Foltz; J R Lutz; J L Anderson
Journal:  J Clin Pharmacol       Date:  1983 Feb-Mar       Impact factor: 3.126

3.  Electrocardiographic and electrophysiologic effects of pirmenol in ventricular tachycardia.

Authors:  N A Estes; R Gold; J Cameron; C Haffajee; M Marshall; K Mack; D N Salem
Journal:  Am J Cardiol       Date:  1987-06-15       Impact factor: 2.778

4.  Pirmenol kinetics and effective oral dose.

Authors:  S C Hammill; D G Shand; F E Harrell; J M Zimmerman; M J Reiter; C Verghese; E L Pritchett
Journal:  Clin Pharmacol Ther       Date:  1982-12       Impact factor: 6.875

5.  Pharmacokinetics and efficacy of pirmenol hydrochloride in the treatment of ventricular dysrhythmia.

Authors:  T G Lee; A D Goldberg; T Chang; M T Serkland; G J Yakatan; E L Johnson; J G Toole; S Goldstein
Journal:  J Cardiovasc Pharmacol       Date:  1983 Jul-Aug       Impact factor: 3.105

6.  Pharmacodynamics and pharmacokinetics of oral pirmenol.

Authors:  K A Ellenbogen; S F Roark; A L Sintetos; M S Smith; E A McCarthy; W M Smith; R E Kates; E L Pritchett
Journal:  Clin Pharmacol Ther       Date:  1987-10       Impact factor: 6.875

7.  Pirmenol, a new antiarrhythmic agent: initial study of efficacy, safety and pharmacokinetics.

Authors:  S C Hammill; D G Shand; P A Routledge; M C Hindman; J T Baker; E L Pritchett
Journal:  Circulation       Date:  1982-02       Impact factor: 29.690

8.  Long-term efficacy of oral pirmenol in suppressing ventricular premature depolarizations.

Authors:  M de Buitleir; B J Crevey; T Johnson; W H Kou; S D Nelson; S Schmaltz; F Morady
Journal:  Am Heart J       Date:  1988-08       Impact factor: 4.749

9.  Electrophysiologic evaluation of pirmenol for sustained ventricular tachycardia secondary to coronary artery disease.

Authors:  A R Easley; D E Mann; M J Reiter; V Sakun; S M Sullivan; S A Magro; J C Luck; C R Wyndham
Journal:  Am J Cardiol       Date:  1986-07-01       Impact factor: 2.778

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.